Epidermal growth factor receptor mutations in lung cancer
- PMID: 17318210
- DOI: 10.1038/nrc2088
Epidermal growth factor receptor mutations in lung cancer
Abstract
The development and clinical application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies. We review the results of genetic, biochemical and clinical studies focused on somatic mutations of EGFR that are associated with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors. Understanding the genetic heterogeneity of epithelial tumours and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.
Similar articles
-
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.Nat Genet. 2005 Dec;37(12):1315-6. doi: 10.1038/ng1671. Epub 2005 Oct 30. Nat Genet. 2005. PMID: 16258541
-
Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.Lung Cancer. 2008 Jun;60 Suppl 2:S10-8. doi: 10.1016/S0169-5002(08)70100-4. Lung Cancer. 2008. PMID: 18513579 Review.
-
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.Cancer Res. 2007 Nov 1;67(21):10417-27. doi: 10.1158/0008-5472.CAN-07-1248. Cancer Res. 2007. PMID: 17974985
-
Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.Oncogene. 2009 Aug;28 Suppl 1:S14-23. doi: 10.1038/onc.2009.197. Oncogene. 2009. PMID: 19680292 Review.
-
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.J Clin Oncol. 2006 May 10;24(14):2158-63. doi: 10.1200/JCO.2006.06.5961. J Clin Oncol. 2006. PMID: 16682734 Review.
Cited by
-
Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.BMC Cancer. 2013 Apr 27;13:210. doi: 10.1186/1471-2407-13-210. BMC Cancer. 2013. PMID: 23621958 Free PMC article.
-
An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs.PLoS One. 2012;7(9):e42441. doi: 10.1371/journal.pone.0042441. Epub 2012 Sep 5. PLoS One. 2012. PMID: 22957020 Free PMC article.
-
Using Vision Transformer for high robustness and generalization in predicting EGFR mutation status in lung adenocarcinoma.Clin Transl Oncol. 2024 Jun;26(6):1438-1445. doi: 10.1007/s12094-023-03366-4. Epub 2024 Jan 9. Clin Transl Oncol. 2024. PMID: 38194018
-
Oncogenic driver mutations in lung cancer.Transl Respir Med. 2013 Dec;1(1):6. doi: 10.1186/2213-0802-1-6. Epub 2013 Mar 8. Transl Respir Med. 2013. PMID: 27234388 Free PMC article. Review.
-
Vandetanib for the treatment of metastatic medullary thyroid cancer.Clin Med Insights Oncol. 2012;6:243-52. doi: 10.4137/CMO.S7999. Epub 2012 Jun 7. Clin Med Insights Oncol. 2012. PMID: 22723734 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous